BERLIN, Germany, October 22, 2020 / B3C newswire / -- ProBioGen AG Berlin, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, & Heidelberg Pharma AG, Ladenburg, Germany, today announced that Heidelberg Pharma has signed a Master Service Agreement for the antibodies used in two of their pipeline Antibody Targeted Amanitin Conjugate (ATAC) molecules.
Under the agreement, ProBioGen is conducting the full service package from cell line development using its CHO.RiGHT® cell line expression platform, incl. its novel DirectedLuck™ Transposase system for the generation of high titer producer clones, over process development till GMP manufacturing of the mAb intermediates of Heidelberg Pharma’s ATAC molecules for cancer indications.
“We are delighted to welcome Heidelberg Pharma, proven experts for the innovative active ingredient Amanitin and ADCs, to our list of international customers”, says Dr. Lutz Hilbrich (MD, MBA), Chief Executive Officer of ProBioGen. “Our longstanding, more than 25 years of experience and positive track record paired with always trend setting new technologies, convinced Heidelberg Pharma to work together with ProBioGen on two of their product candidates to advance them into clinical studies with the ultimate aim to serve and help patients in need. We are strongly committed to our customers and their needs, and in line with demand we are looking forward to continuous collaborations based on already increased and further increasing production capacity.”
“Working with the right partner is a critical element in developing a compelling product candidate”, said Dr. Jan Schmidt-Brand, Heidelberg Pharma’s Chief Executive Officer. “Thus we are excited to work with ProBioGen as they have both, the technical expertise and a very committed team. ProBioGen is well known in the community to provide highest quality in proven timelines. Heidelberg Pharma’s commitment to developing life-changing therapies for patients is a perfect match for their focus on the client’s needs.”
About Heidelberg Pharma AG
Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company’s proprietary therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma.
About ProBioGen AG
ProBioGen is a Contract Development and Manufacturing Organization (CDMO) and technology provider with extensive expertise in cell line engineering, process development and GMP manufacturing of biopharmaceuticals. Our proprietary technologies like CHO.RiGHT®, the genetic Glyco-Engineering GlymaxX® and the targeted transposase DirectedLuck™ in combination with our efficient process development and robust GMP manufacturing accelerate and advance the development of drug candidates – from early concept to industrial market-readiness.
ProBioGen provides modern manufacturing solutions for viral vectors with its continuous AGE1.CR® duck cell line, a vaccine platform with MVA-CR19 and renders technology support in gene therapy and vaccine development.
All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen is successfully serving international clients for more than 26 years, is privately owned and based in Berlin.
Dr. Gabriele Schneider
Chief Business Officer
13086 Berlin, Germany
+49 (0)30 3229 35 100
Keywords: Cell Line; Biological Products; Cells, Cultured; cell line development; productivity; Transposases; CHO Cells; Glycoproteins; Neoplasms; Amanitins; Germany
Published by B3C newswire